Related references
Note: Only part of the references are listed.Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic alpha-synuclein oligomers in Parkinson's disease
Nouara Yahi et al.
GLYCOCONJUGATE JOURNAL (2022)
Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
mRNA vaccine: a potential therapeutic strategy
Yang Wang et al.
MOLECULAR CANCER (2021)
Gene therapy using Aβvariants for amyloid reduction
Kyung-Won Park et al.
MOLECULAR THERAPY (2021)
Glucocerebrosidase as a therapeutic target for Parkinson's disease
Yu Chen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal
Jacques Fantini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Recent advances in mRNA vaccine technology
Norbert Pardi et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?
Jacques Fantini et al.
PROTEIN SCIENCE (2020)
Gene Therapy Vector Encoding Neuropeptide Y and Its Receptor Y2 for Future Treatment of Epilepsy: Preclinical Data in Rats
Julia Alicja Szczygiel et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)
Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer's disease
Marina Dukhinova et al.
NEUROBIOLOGY OF AGING (2019)
Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B
Alessandra Flores et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Gangliosides: Treatment Avenues in Neurodegenerative Disease
Pierre J. Magistretti et al.
FRONTIERS IN NEUROLOGY (2019)
Therapeutic peptides for CNS indications: Progress and challenges
Bruce H. Morimoto
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade
Erika N. Cline et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Pathological role of lipid interaction with α-synuclein in Parkinson's disease
Mani Suzuki et al.
NEUROCHEMISTRY INTERNATIONAL (2018)
The Emerging Evidence of the Parkinson Pandemic
E. Ray Dorsey et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload
Roberta Cascella et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Physico-Pathologic Mechanisms Involved in Neurodegeneration: Misfolded Protein-Plasma Membrane Interactions
Amulya Nidhi Shrivastava et al.
NEURON (2017)
The past, present, and future of disease-modifying therapies for Alzheimer's disease
Kazushi Suzuki et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)
Motor Complications of Dopaminergic Medications in Parkinson's Disease
Maria Eliza Freitas et al.
SEMINARS IN NEUROLOGY (2017)
Gene therapy for neurological disorders
Chi-Jing Choong et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides
Coralie Di Scala et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2016)
Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches
Parveen Salahuddin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Alzheimer's and Parkinson's Diseases: Expected Economic Impact on Europe-A Call for a Uniform European Strategy
Petra Maresova et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Alpha-Synuclein Oligomers-Neurotoxic Moleculesin Parkinson's Disease and Other Lewy Body Disorders
Martin Ingelsson
FRONTIERS IN NEUROSCIENCE (2016)
Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein
Coralie Di Scala et al.
SCIENTIFIC REPORTS (2016)
Comparison of the amyloid pore forming properties of rat and human Alzheimer's beta-amyloid peptide 1-42: Calcium imaging data
Coralie Di Scala et al.
DATA IN BRIEF (2016)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Extracellular alpha-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane
Carla R. Pacheco et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Edward Rockenstein et al.
BRAIN (2014)
Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs
Hyunbum Jang et al.
CHEMICAL SOCIETY REVIEWS (2014)
Noninvasive near-infrared fluorescent protein-based imaging of tumor progression and metastases in deep organs and intraosseous tissues
Carine Jiguet-Jiglaire et al.
JOURNAL OF BIOMEDICAL OPTICS (2014)
Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide
Coralie Di Scala et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Stephane Palfi et al.
LANCET (2014)
Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult
William I. Rosenblum
NEUROBIOLOGY OF AGING (2014)
Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes
Soyon Hong et al.
NEURON (2014)
Deciphering the Glycolipid Code of Alzheimer's and Parkinson's Amyloid Proteins Allowed the Creation of a Universal Ganglioside-Binding Peptide
Nouara Yahi et al.
PLOS ONE (2014)
Amyloid-Beta Oligomerization in Alzheimer Dementia versus High-Pathology Controls
Thomas J. Esparza et al.
ANNALS OF NEUROLOGY (2013)
Immunotherapy for Alzheimer's disease: hoops and hurdles
Cynthia A. Lemere
MOLECULAR NEURODEGENERATION (2013)
Alzheimer's disease: which type of amyloid-preventing drug agents to employ?
Hyunbum Jang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2013)
Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by α-Synuclein Oligomers in Lipid Membranes
Felix Schmidt et al.
PLOS ONE (2012)
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Molecular Basis for the Glycosphingolipid-Binding Specificity of α-Synuclein: Key Role of Tyrosine 39 in Membrane Insertion
Jacques Fantini et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Bright and stable near-infrared fluorescent protein for in vivo imaging
Grigory S. Filonov et al.
NATURE BIOTECHNOLOGY (2011)
Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
Ming Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases
Jacques Fantini et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2010)
Protein aggregation in the brain: The molecular basis for Alzheimer's and Parkinson's diseases
G. Brent Irvine et al.
MOLECULAR MEDICINE (2008)
Different species of α-synuclein oligomers induce calcium influx and seeding
Karin M. Danzer et al.
JOURNAL OF NEUROSCIENCE (2007)
Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide
Christian Haass et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
A beta Oligomers - a decade of discovery
Dominic M. Walsh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Inhibitors of α-synuclein oligomerization and toxicity:: a future therapeutic strategy for Parkinson's disease and related disorders
Dena A. M. Amer et al.
EXPERIMENTAL BRAIN RESEARCH (2006)
Neuropathology of older persons without cognitive impairment from two community-based studies
D. A. Bennett et al.
NEUROLOGY (2006)
Amyloid ion channels: A common structural link for protein-misfolding disease
A Quist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Transgene expression of α(1,2)-fucosyltransferase-I (FUT1) in tumor cells selectively inhibits sialyl-Lewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis a or binding to P-selectin
S Mathieu et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Share Paper
